Rannard, Steve - University of Liverpool

个人简介

Steve graduated from the University of Sussex having completed a first degree and latterly his D.Phil studies (sponsored by BP, Sunbury-on-Thames) with Prof. Norman Billingham on controlled amphiphilic block copolymers for dialysis membranes. After his D.Phil, Steve joined the Cookson Technology Centre in Oxford (Organic Materials Group). After 2 years he moved to the Courtaulds (Coventry) where he worked for 4.5 years in the Strategic Research and the Coatings & Sealants Groups before moving to the Unilever R&D laboratories at Port Sunlight. He had several roles during his 9 years at Unilever but was closely linked to the chemistry groups both in the UK and China (Shanghai) throughout that period. Initially he was Unit Leader but he progressed to Science Area Leader and finally Discovery Platform Director. Steve held a Royal Society Industry Fellowship ( 2005-2009) and an IOTA NanoSolutions Fellowship (2007-2010). He was the first recipient of the joint RSC/Macro Group UK Young Researcher of the Year Medal (1998) for his branched polymer and dendrimer research (Courtaulds). Steve has also co-founded three spin-out companies, Hydra Polymers Limited (purchased by Parogle Technologies), IOTA NanoSolutions Limited and Tandem Nano Ltd. He had roles as CEO and Chief Scientific Officer within IOTA NanoSolutions and was Chief Scientific Advisor and non-Executive Director at Hydra. IOTA was the winner of the NorthWest Regional Science and Technology Business of the Year Award (2007), Merseyside Innovation Award (2007) and the NorthWest Biomedical Startup of the Year Award (2007). It was also highlighted as RSC SME of the Month in September 2007. After joining Liverpool in September 2007, Steve has developed a Nanomedicine Research Group with very strong interactions with infectious pharmacology (Prof Andrew Owen, UoL). Between 2008-2015, the collective research funding for the collaborative nanomedicine activities has been in excess of £11m, with a strong emphasis on new therapies for HIV treatment. Two nanomedicine programmes have received MHRA approval for human clinical trials. This has been largely supported by UK research councils, US Government funding and international charities. Industrial comntributions and funding have also been important to the group's activities. Steve was a founding committee member of the Recent Appointees in Polymer Science Group (RAPS), committee member of the High Polymer Research Group (2001-2006), member of the Organic Materials Innovation Centre Management Team (2002-2006), RSC Industrial Lecturer Strathclyde University (2001) and the University of Sussex (2002), visiting Lecturer at University of Sussex (1999-2001), visiting Professor at the University of Liverpool (2003-2007), member of the Applied Polymer Science Committee (Institute of Materials) (1997-2000) and committee member of the Macro Group UK (1998-2002) and acts as an advisor to the Welsh Government in the Ser Cymru (Welsh Stars) academic strategy programme. He has also co-founded the British Society for Nanomedicine and the Journal of Interdisciplinary Nanomedicine where he acts as Co-Editor in Chief. Invited Speaker at International Conference (Invitation to Speak, ELRIG 2010) Invited Speaker at International Conference (Invitation to Speak, INFORMA 2010) Invited Speaker at International Conference (Invitation to Speak, FORMULA VI 2010) Plenary Lecture (Keynote Speech, BHIVA 2009) Plenary Lecture (Invitation to Speak, Cambridge Armourers and Brasiers 2009) Plenary Lecture (Invitation to Speak, Bristish Association of Science 2008) Invitation to Present (Invitation to Speak, SCI 2007) Invited Speaker at International Conference (Invitation to Speak, PDDG 2007) Plenary Speaker (Invitation to Speak, RSC 2007)

研究领域

Please see the Rannard Group website http://rannardgroup.wix.com/rannardgroup for full details of our current research, archives of our publications and current vacancies. The group researches novel polymer chemistry and organic nanoparticle production for many potential applications including nanomedicine. Within our nanomedicine programmes, we are highly focussed on infectious diseases including HIV, where our outputs are targeting clinically relevant translational technologies.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies Model studies of the sequential and simultaneous statistical modification of dendritic functional groups and their implications within complex polymer architecture synthesis Abstract Amphiphilic branched copolymer emulsifiers, methods of preparation, emulsions, and uses Amphiphilic branched polymers and their use as emulsifiers Aqueous media purification method and device comprising a functionalised polyhipe resin Azetidinium modified polymers and fabric treatment composition Branched addition copolymers and their use Branched copolymers, composition and uses Branched polymer dispersants Carrier liquids containing silicones for personal care products Cleaning and rinsing of textile fabrics and composite wash product Compositions comprising porous matrix having active ingredient in the form of nanoparticle, and production thereof. Compositions of efavirenz Compositions of lopinavir Controlling drug release from non-aqueous environments: Moderating delivery from ocular silicone oil drug reservoirs to combat proliferative vitreoretinopathy Delivery system for an active agent Dendritic polymers based on carbonyldiimidazole Early Investigation of the Stabilisation Effects of Polymer and Surfactant Combinations in the Formulation of Solid Drug Nanoparticles Exploring Hyperbranched-Polydendron Chemistry and Architecture for Nanomedicine Applications Hard surface cleaner containing antioxidants Hard surface cleaning compositions containing hyperbranched polymer Hydrophilic branched copolymers, composition and uses Improvements relating to antiparasitic nanodisperse compositions comprising water-soluble carriers Improvements relating to antiviral compositions